Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorLuxembourg Institute of Health

About this trial

The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.

Eligibility criteria

Qualifiers

Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)

Subjects of all genders with a full capacity of consent

Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement

Subjects of at least 18 years of age at the time of inclusion

Disqualifiers

Refusal to sign the informed consent

Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion

Active cancer

Pregnant women

Trial design

Treatments tested in this trial

  • Observational study with sample and data collection

Treatment groups

1,800 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Luxembourg Institute of Health

Lead sponsor

University of Luxembourg

Collaborator

Laboratoire National de Santé (LNS)

Collaborator

Centre Hospitalier du Luxembourg

Collaborator